|Day Low/High||4.20 / 4.26|
|52 Wk Low/High||3.60 / 6.92|
- World's largest influenza vaccine manufacturer expects to distribute more than 65 million vaccine doses to help protect people six months and older against the flu -
Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the first adult patient has enrolled and been dosed in a pivotal Phase 2/3 clinical trial named ASCEND for the investigational...
A passing grade is essentially a green light for financial institutions to boost capital deployment programs.
There's a reason it is buying its own stock hand over fist.
U.S. stock futures are pointing to a third day of gains on Wall Street.
The U.S. units of the two European lenders were the only failures in the latest stress tests.
Figures paint a picture of weak consumer demand in Europe's three largest economies.
Morgan Stanley passed this year's Federal Reserve "stress tests" -- with a footnote. The firm can proceed with dividends and share buybacks but must fix certain weaknesses.
The U.S. units of Deutsche Bank and Banco Santander continue to have problems, while Morgan Stanley must resubmit its capital distribution plan by the end of December or fail.
Despite shares of Banco Santander (SAN) dropping in high-volume trade today, the bank reiterates its financial targets for the year.
Here's a technical look at how to trade some of the most active stock on the market right now.
Banco Santander (SAN) stock is retreating as shares of financial institutions take a hit after the U.K. decided to exit the European Union.
Banks plunge, with U.K. home builders, automakers, and food retailers also posting steep declines.
Banks plunge, with U.K. home builders and food retailers also posting steep declines.
Close to 40% of Dollars Donated Support Financial Education Programs in Low- and Moderate-Income Communities
We see protection/fear bets creeping in, and today's price action is a bit discouraging.
- FDA decisions on the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide and investigational lixisenatide anticipated in Q3 2016 -
Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today the launch of vs.
Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today a research collaboration with the Johns Hopkins School of Medicine that will focus on novel strategies aimed at advancing the...
MPV APLE SAN are going ex-dividend tomorrow, Thursday, April 28, 2016
Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced that positive new brain volume data from an ongoing clinical study of Lemtrada ® (alemtuzumab) will be presented at the 68th...
Bank's New Tablet and Desktop Account Opening Platform Wins Celent's Prestigious Model Bank Award in the Digital Banking Transformation Category